EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,534,596 | +35.5% | 1,214,398 | +18.5% | 0.01% | +50.0% |
| Q2 2023 | $19,585,552 | -19.2% | 1,024,885 | -18.0% | 0.00% | -20.0% |
| Q1 2023 | $24,247,399 | +93.4% | 1,249,222 | +59.8% | 0.01% | +25.0% |
| Q4 2022 | $12,535,533 | -24.6% | 781,517 | -26.3% | 0.00% | 0.0% |
| Q3 2022 | $16,631,000 | -3.2% | 1,060,688 | +28.5% | 0.00% | 0.0% |
| Q2 2022 | $17,185,000 | +9.5% | 825,407 | +19.2% | 0.00% | +33.3% |
| Q1 2022 | $15,701,000 | -47.5% | 692,592 | -57.7% | 0.00% | – |
| Q4 2021 | $29,932,000 | +64.7% | 1,637,500 | +90.5% | 0.00% | -100.0% |
| Q3 2021 | $18,171,000 | -1.7% | 859,505 | -15.3% | 0.00% | 0.0% |
| Q2 2021 | $18,484,000 | -20.6% | 1,014,459 | -1.6% | 0.00% | 0.0% |
| Q1 2021 | $23,279,000 | -48.0% | 1,030,489 | -53.8% | 0.00% | -25.0% |
| Q4 2020 | $44,810,000 | +59.3% | 2,232,720 | +94.1% | 0.00% | -20.0% |
| Q3 2020 | $28,125,000 | +9.0% | 1,150,303 | +5.9% | 0.01% | 0.0% |
| Q2 2020 | $25,794,000 | +12.8% | 1,086,519 | -18.2% | 0.01% | -28.6% |
| Q1 2020 | $22,873,000 | -26.5% | 1,328,236 | -24.8% | 0.01% | -22.2% |
| Q4 2019 | $31,104,000 | -43.4% | 1,765,276 | -43.2% | 0.01% | -52.6% |
| Q3 2019 | $54,981,000 | -78.3% | 3,108,929 | -73.8% | 0.02% | -38.7% |
| Q2 2019 | $253,853,000 | +196.5% | 11,878,931 | +230.2% | 0.03% | -11.4% |
| Q1 2019 | $85,612,000 | +38.3% | 3,597,148 | +14.3% | 0.04% | +40.0% |
| Q4 2018 | $61,912,000 | +27.1% | 3,147,505 | +14.5% | 0.02% | +56.2% |
| Q3 2018 | $48,711,000 | +75.3% | 2,748,936 | +112.9% | 0.02% | +77.8% |
| Q2 2018 | $27,782,000 | -58.1% | 1,290,998 | -56.8% | 0.01% | -60.9% |
| Q1 2018 | $66,244,000 | -43.6% | 2,990,695 | -22.6% | 0.02% | -43.9% |
| Q4 2017 | $117,440,000 | +118.8% | 3,863,142 | +74.4% | 0.04% | +95.2% |
| Q3 2017 | $53,678,000 | -2.8% | 2,215,315 | -1.2% | 0.02% | -12.5% |
| Q2 2017 | $55,203,000 | +36.1% | 2,241,303 | +19.7% | 0.02% | +20.0% |
| Q1 2017 | $40,569,000 | +66.2% | 1,872,144 | +14.4% | 0.02% | +66.7% |
| Q4 2016 | $24,403,000 | -2.5% | 1,636,654 | -16.4% | 0.01% | 0.0% |
| Q3 2016 | $25,034,000 | +116.1% | 1,957,300 | +32.0% | 0.01% | +100.0% |
| Q2 2016 | $11,583,000 | +152.8% | 1,483,215 | +29.5% | 0.01% | +200.0% |
| Q1 2016 | $4,581,000 | -41.8% | 1,145,336 | -17.9% | 0.00% | -50.0% |
| Q4 2015 | $7,868,000 | -4.5% | 1,395,001 | -5.0% | 0.00% | +33.3% |
| Q3 2015 | $8,241,000 | +29.1% | 1,468,921 | -13.5% | 0.00% | 0.0% |
| Q2 2015 | $6,384,000 | +89.8% | 1,697,874 | +29.8% | 0.00% | +200.0% |
| Q1 2015 | $3,363,000 | -6.7% | 1,308,547 | -47.7% | 0.00% | -50.0% |
| Q4 2014 | $3,603,000 | -29.6% | 2,501,837 | -25.2% | 0.00% | -33.3% |
| Q3 2014 | $5,118,000 | -51.2% | 3,344,942 | +8.1% | 0.00% | -25.0% |
| Q2 2014 | $10,489,000 | -20.4% | 3,093,697 | -16.9% | 0.00% | -33.3% |
| Q1 2014 | $13,179,000 | +105.6% | 3,722,922 | +256.0% | 0.01% | +100.0% |
| Q4 2013 | $6,409,000 | +63.5% | 1,045,720 | +55.3% | 0.00% | +50.0% |
| Q3 2013 | $3,920,000 | +50.5% | 673,351 | +17.4% | 0.00% | +100.0% |
| Q2 2013 | $2,604,000 | – | 573,592 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |